Médecins pour Tumeur surrénale à l'étranger — Page 3

Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

L'Assoc. Prof. Nail Paksoy combine plus de 11 ans d'expérience spécialisée en oncologie avec une participation active à 8 essais internationaux sur le cancer à l'hôpital Medipol Bahçelievler.

• Certifié par l'ESMO en oncologie médicale
• Spécialisé dans les cas de tumeurs surrénaliennes et rares
• Plus de 30 études évaluées par des pairs publiées sur les traitements oncologiques
• Stage de spécialisation effectué à l'Institut d'oncologie de l'Université d'Istanbul

Formé en chirurgie laparoscopique avancée à l'Université d'Istanbul – spécialisé dans les procédures mini-invasives pour les tumeurs surrénaliennes.

• Plus de 20 ans d'expérience chirurgicale
• Formation spécialisée complétée en chirurgie laparoscopique bariatrique et oncologique
• Travaille aux hôpitaux Büyük Anadolu – un centre médical de premier plan

Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.

He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.

His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.

Dr. Maha Yahia is a medical oncologist and hemato-oncologist. She provides assessment, diagnosis, and treatment planning. Her treatments include chemotherapy, targeted therapy, and immunotherapy. She cares for patients with breast, genitourinary, gynecologic, thoracic, gastrointestinal, and rare cancers.

Education: M.B.B.Ch, Kasr El-Aini, Cairo University (1997–2003). Master in Hemato-oncology, National Cancer Institute, Cairo University (2008). Doctoral Degree in Hemato-oncology, National Cancer Institute, Cairo University (2015).

Experience: Resident in Medical Oncology, Maadi AFMC (2005–2010). Visitor Resident, NCI Cairo (2008–2009). Consultant Assistant, Prof. Hussein Khaled Clinic (2010–2017). Specialist, International Medical Center (2011–2012), Wadi El Nile Hospital (2013–2014), and Maadi AFMC (2011–2018). Head, Clinical Research Support Team, Maadi AFMC (2016–2018). Major (2014–2016) and Lt. Colonel Doctor (2016–2018), Egyptian Armed Forces. Lecturer of Clinical Research, AFCM (2019–2021).

Dr. Emad Shash, M.B.B.Ch, MSc, M.D., is a medical oncologist. He is the Medical Director of the Breast Comprehensive Cancer Hospital at NCI. He leads the Medical Oncology Department and is the Breast Program Director at Shifaa Al Orman Cancer Hospital in Luxor. His clinical focus includes breast, gynecologic, genitourinary, thoracic, gastrointestinal, and rare cancers. He specializes in systemic therapy, including chemotherapy, targeted therapy, and immunotherapy.

He served as coordinating research physician and medical lead at the EORTC from 2011 to 2015. Since 2008, he has contributed to more than 70 international oncology trials as a coordinator, sub-investigator, principal investigator, and sponsor medical monitor. Credentials include M.B.B.Ch (2004), MSc (2010), MD (2015), and the EORTC Certificate of Excellence (2015). He also holds a Diploma in Hospital Quality Management & Patient Safety (JCI/57357, 2017). He is a Fellow of the EIO. He is a member of ESMO (panel voting), ESGO, and ASCO (IAC), and serves on the ECRIN board.

Dr. Zohar Dotan is Head of the Urology Department at Sheba Medical Center. He is a leading uro-oncologist and a pioneer of robotic and laparoscopic urologic surgery in Israel.

He has authored more than 50 scientific publications. He is a regular speaker at international conferences. He has received awards from the American Association of Clinical Surgery, including recognition for research in prostate cancer treatment.

Leadership and credentials: Head of the Israeli Uro-Oncology Society. Assistant Professor at Tel Aviv University. Member of the Israeli, American, and European Urological Associations. Training: MD from Tel Aviv University and a PhD in Genetics. Urology residency at Sheba Medical Center. Fellowship in uro-oncology and laparoscopic surgery at Memorial Sloan Kettering, New York.

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.

Dr. Nir Kleinmann, MD, directs the Endourology and Kidney Stones Unit at Sheba Medical Center. He is an expert in minimally invasive urology and urologic oncology. His focus is the kidney and upper urinary tract. He was named among Israel’s Best Doctors for 2025–2026 by Forbes and ResultMed.

He is a pioneer of kidney‑sparing laser surgery. He uses a dual‑laser system with neodymium and holmium for complex tumors. His expertise includes UTUC, kidney and prostate cancer, kidney stones, and BPH.

His research includes the OLYMPUS trial on chemoablation for UTUC. He has more than 60 publications.

He is an Israeli board‑certified urologist. He is a Fellow of the American Endourology Society and a member of the Israeli Urological Association and the EAU. He completed fellowships in Endourology and Minimally Invasive Surgery at Thomas Jefferson University. He also completed a fellowship in Kidney Cancer Research at McMaster University.

Le Dr Volkan Kinas est spécialisé en chirurgie oncologique, avec un accent particulier sur les cas de tumeurs complexes aux hôpitaux Büyük Anadolu.

• Expert en chirurgie du pancréas, des voies biliaires et des tumeurs surrénaliennes
• Compétent dans les techniques traditionnelles et mini-invasives
• Réaliser des chirurgies du cancer du sein, de l'estomac et du côlon

Spécialisation en radio-oncologie à l'Université de Marmara – formation ciblée sur les traitements avancés des tumeurs surrénaliennes.

• Plus de 6 ans d'expérience spécialisée en radio-oncologie
• Diplômé de la Faculté de médecine de l'Université de Marmara (programme en anglais)
• Travaille à l'hôpital Emsey, un établissement de premier plan pour les soins oncologiques

Le Prof. Filippini est spécialisé dans le traitement chirurgical des tumeurs localement avancées et les résections multi-organes, ayant été formé dans les meilleurs centres américains tels que le Memorial Sloan Kettering.

• Plus de 40 ans d'expérience en chirurgie oncologique
• Formé aux techniques mini-invasives et robotiques aux États-Unis
• Auteur de plus de 100 publications scientifiques
• Professeur à l'Université de Chieti depuis les années 1990

Le professeur Ahmet Cag Cal apporte des décennies d'expérience spécialisée en urologie, incluant une formation au Memorial Sloan-Kettering Cancer Center et à l'UCLA.

• Plus de 30 ans de pratique en urologie
• Formation de type "Fellowship" à la Mayo Clinic du Minnesota
• Actuel professeur à l'hôpital Medicana Bursa
• Spécialisation dans les chirurgies urologiques complexes
• Recherches publiées en urologie et en génétique moléculaire

Le Dr Shruti Kate est spécialisée dans le traitement des tumeurs surrénaliennes, avec un accent particulier sur l'immunothérapie et la thérapie métronomique pour les cancers avancés. Elle a été formée au Tata Memorial Hospital, l'un des centres de cancérologie les plus réputés d'Inde.

• DM en oncologie médicale du Tata Memorial Hospital
• Experte en cancers du poumon, du sein et génito-urinaires
• Membre de l'ASCO, de l'ESMO et d'autres sociétés oncologiques prestigieuses
• Présenter des recherches lors de la Conférence mondiale sur le cancer du poumon